Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/24/suppl_10/x53/6675005/mdt472.pdf
Reference23 articles.
1. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nat Rev Clin Oncol,2013
2. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer;Monk;Crit Rev Oncol Hematol,2013
3. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model;Mabuchi;Clin Cancer Res,2008
4. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer;Monk;Gynecol Oncol,2005
5. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer;Monk;Gynecol Oncol,2006
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy;International Journal of Gynecologic Cancer;2023-01-27
2. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study;European Journal of Gynaecological Oncology;2023
3. Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature;SAGE Open Medical Case Reports;2023-01
4. Monoclonal Antibody and Targeted Toxin Therapy;Holland‐Frei Cancer Medicine;2022-10-21
5. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer;Frontiers in Endocrinology;2022-05-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3